Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Analysts at Chardan Capital increased their FY2023 earnings per share (EPS) estimates for shares of Gain Therapeutics in a research report issued on Wednesday, November 15th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings per share of ($1.57) for the year, up from their prior estimate of ($1.95). Chardan Capital currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.83) per share. Chardan Capital also issued estimates for Gain Therapeutics’ FY2024 earnings at ($1.28) EPS.
GANX has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Gain Therapeutics in a research report on Monday, September 18th. Maxim Group assumed coverage on Gain Therapeutics in a research report on Tuesday, September 12th. They set a “buy” rating and a $10.00 price target on the stock.
Gain Therapeutics Price Performance
Shares of GANX stock opened at $2.70 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.10 and a current ratio of 2.30. Gain Therapeutics has a fifty-two week low of $2.56 and a fifty-two week high of $6.19. The firm has a market cap of $34.86 million, a P/E ratio of -1.49 and a beta of 0.35. The business’s 50 day moving average price is $3.14 and its 200-day moving average price is $3.92.
Institutional Investors Weigh In On Gain Therapeutics
Several hedge funds have recently added to or reduced their stakes in GANX. Royal Bank of Canada raised its stake in shares of Gain Therapeutics by 947.6% in the third quarter. Royal Bank of Canada now owns 210,000 shares of the company’s stock worth $689,000 after purchasing an additional 189,954 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Gain Therapeutics by 23.0% in the second quarter. Renaissance Technologies LLC now owns 47,600 shares of the company’s stock worth $213,000 after purchasing an additional 8,900 shares during the last quarter. BlackRock Inc. raised its stake in shares of Gain Therapeutics by 17.1% in the second quarter. BlackRock Inc. now owns 29,024 shares of the company’s stock worth $130,000 after purchasing an additional 4,246 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Gain Therapeutics by 47.3% in the second quarter. Geode Capital Management LLC now owns 138,721 shares of the company’s stock worth $621,000 after purchasing an additional 44,514 shares during the last quarter. Finally, Raymond James & Associates raised its stake in shares of Gain Therapeutics by 67.0% in the second quarter. Raymond James & Associates now owns 33,400 shares of the company’s stock worth $150,000 after purchasing an additional 13,400 shares during the last quarter. 9.99% of the stock is owned by institutional investors.
Gain Therapeutics Company Profile
Gain Therapeutics, Inc, a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.
- Five stocks we like better than Gain Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Investing in Construction Stocks
- MarketBeat Week in Review – 11/13 – 11/17
- How to Calculate Stock Profit
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.